Table 1.
Patient demographics
| Baseline characteristics | N=18 |
| Age (years) | |
| Median (range) | 71.6 (54–88) |
| Race | |
| White/Caucasian | 15 |
| Black | 3 |
| ECOG PS (N, %) | |
| 0 | 7 |
| 1 | 11 |
| Gleason score | |
| Median (range) | 8 (6–9) |
| Baseline PSA (ng/mL) (range) | 25.58 (0.62–1006) |
| Prior therapies | |
| Chemotherapy (CSPC) | 10 |
| Chemotherapy (CRPC) | 6 |
| Therapeutic cancer vaccine | 7 |
| Immune checkpoint inhibitor | 6 |
| Abiraterone | 12 |
| Enzalutamide | 12 |
| PARP inhibitors | 4 |
| ADT only (mCRPC treatment-naïve) | 5 |
| Number of prior mCRPC therapies | |
| Median (range) | 3 (0–7) |
ADT, androgen-deprivation therapy; CRPC, castration-resistant prostate cancer; CSPC, castration-sensitive prostate cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Score; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly ADP ribose polymerase; PSA, prostate-specific antigen.